ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Disease Activity"

  • Abstract Number: 2828 • 2014 ACR/ARHP Annual Meeting

    A Physically Demanding Job May Amplify the Effect of Disease Activity on the Development of Syndesmophytes in Patients with Ankylosing Spondylitis

    Sofia Ramiro1,2, A.M. van Tubergen3, Robert Landewé4,5, Annelies Boonen6, Carmen Stolwijk7, Maxime Dougados8, Filip van Den Bosch9 and Desiree van der Heijde10, 1Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center/University of Amsterdam, Amsterdam, Netherlands, 2Rheumatology, Hospital Garcia de Orta, Almada, Portugal, 3Department of Internal Medicine, Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, 4Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 5Atrium Medical Center, Heerlen, Netherlands, 6Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, 7Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, 8Université Paris René Descartes and Hôpital Cochin, Paris, France, 9Ghent University Hospital, Ghent, Belgium, 10Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose:  We have recently shown that disease activity is longitudinally associated with radiographic progression in AS. In animal models, it has recently been shown that…
  • Abstract Number: 2456 • 2014 ACR/ARHP Annual Meeting

    Associations of Toll-like Receptor (TLR)-4 Single Nucleotide Polymorphisms and Rheumatoid Arthritis Disease Progression

    Marshall Davis1, Tricia LeVan2, Fang Yu3, Harlan Sayles4, Jeremy Sokolove5, William H. Robinson6, Kaleb Michaud7, Geoffrey M Thiele8 and Ted R. Mikuls4, 1Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 2Univ of Nebraska Med Ctr, Omaha, NE, 3University of Nebraska Medical Center, Omaha, NE, 4Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 5VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, 6VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, 7National Data Bank for Rheumatic Diseases, Wichita, KS, 8Omaha VA and the University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Toll-like receptor (TLR)-4 signaling pathways have been implicated in both the innate and adaptive immune responses that characterize rheumatoid arthritis (RA).  In this study,…
  • Abstract Number: 1921 • 2014 ACR/ARHP Annual Meeting

    The Deposition of Complement C4d Split Product on Platelets and Erythrocytes Correlate with Disease Activity and Improvement in Systemic Lupus Erythematosus

    Joan T. Merrill1, Aikaterini Thanou2, Stan Kamp1, John Conklin3, Derren Barken4 and Thierry Dervieux5, 1Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Arthritis and Clinical Immmunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 31261 Liberty Way Suite C, Exagen Diagnostics, Inc., Vista, CA, 4Exagen Diagnostics, Inc., Vista, CA, 5rd, Exagen Diagnostics, Inc., Vista, CA

    Background/Purpose: We sought to evaluate the usefulness of cell bound complement activation products (C4d deposition on erythrocytes [EC4d] and platelets [PC4d]) in the monitoring of…
  • Abstract Number: 1452 • 2014 ACR/ARHP Annual Meeting

    Timing of Decisions to Adjust Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy for Rheumatoid Arthritis (RA) Patients with Active Disease in a Usual Practice Setting

    Yomei Shaw1, Chung-Chou H. Chang2, Marc C. Levesque3, Julie M. Donohue4, Kaleb Michaud5,6 and Mark S. Roberts1, 1Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, 2Department of Medicine, University of Pittsburgh Department of Medicine, Pittsburgh, PA, 3Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA, 4Health Policy & Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, 5National Data Bank for Rheumatic Diseases, Wichita, KS, 6Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Current guidelines recommend that rheumatoid arthritis (RA) patients with poor response to their current regimen of disease modifying anti-rheumatic drugs (DMARDs) have therapy adjusted…
  • Abstract Number: 1053 • 2014 ACR/ARHP Annual Meeting

    Co-Morbidity Is Associated with Disease Severity in Early Rheumatoid Arthritis

    Christopher Sparks1, Aleena Abdullah2, Steven Zhao3, Cristina Estrach3 and Nicola Goodson1, 1Musculoskeletal Biology1, University of Liverpool, Liverpool, United Kingdom, 2Musculoskeletal biology1, University of Liverpool, Liverpool, United Kingdom, 3Rheumatology, University Hospital Aintree, Liverpool, United Kingdom

    Background/Purpose Co-morbidity has been shown to increase length of hospital stay and mortality in hospitalised patients. However, in early rheumatoid arthritis (eRA) co-morbidity may confound…
  • Abstract Number: 709 • 2014 ACR/ARHP Annual Meeting

    Impact of Sleep Disorders in Quality of Life, Pain and Disease Activity Using Actigraphy and  Pittsburgh Sleep Quality Index (PSQI)in Female with Systemic Lupus Ertyhematosus (SLE).

    Lilian Reis1, Marco Tulio de Mello2 and Virginia M. Trevisani3, 1Internal medicine and therapy, Federal University of Sao Paulo - UNIFESP, SAO PAULO, Brazil, 2Department of Psychobiology, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil, 3Federal University of São Paulo, São Paulo Brazil, Brazil

    Background/Purpose Despite the fact that sleep disorders are poorly studied, they´re a frequent complain by patients with SLE (62 to 80% related) and others found…
  • Abstract Number: 383 • 2014 ACR/ARHP Annual Meeting

    How Low Is Low Disease Activity? an Analysis from a Prospective, Observational Registry

    Edward C. Keystone1, Boulos Haraoui2, John Kelsall3, Carter Thorne4, Philip Baer5, William Bensen6, Denis Choquette7, Regan Arendse8, Dalton Sholter9, Niall Jones10, Algis Jovaisas11, Emmanouil Rampakakis12, John S. Sampalis12, Francois Nantel13, May Shawi13, Allen J Lehman14 and Susan Otawa14, 1Medicine, University of Toronto, Toronto, ON, Canada, 2University of Montreal Hospital Centre, Montreal, QC, Canada, 3The Mary Pack Arthritis Centre, Vancouver, BC, Canada, 4Southlake Regional Health Centre, Newmarket, ON, Canada, 5Private Practice, Scarborough, ON, Canada, 6St Josephs Hospital and McMaster University, Hamilton, ON, Canada, 7Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 8University of Saskatchewan, Saskatoon, SK, Canada, 9University of Alberta, Edmonton, AB, Canada, 10Dept of Rheumatology, University of Alberta, Edmonton, AB, Canada, 11194 Main Street, University of Ottawa, Ottawa, ON, Canada, 12JSS Medical Research, Montreal, QC, Canada, 13Janssen Inc., Toronto, ON, Canada, 14Medical Affairs, Janssen Inc., Toronto, ON, Canada

    Background/Purpose: Composite measures of disease activity can facilitate clinical decision-making to achieve treatment goals, and treating-to-target has been shown to improve outcomes. Both CRA and…
  • Abstract Number: 136 • 2014 ACR/ARHP Annual Meeting

    Serum Calprotectin (S100A8/9) Is an Independent Predictor of Ultrasound Synovitis in Patients with Rheumatoid Arthritis

    Jana Hurnakova1, Jakub Zavada1, Petra Hanova2, Hana Hulejova1, Martin Klein1, Herman F. Mann1, Olga Sleglova1, Martina Olejarova1, Sarka Forejtova3, Olga Ruzickova1, Martin Komarc4, Karel Pavelka1 and Ladislav Senolt3, 1Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, 2Institute of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, 3Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 4Institute of biophysics and informatics, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic

    Background/Purpose Serological biomarkers specifically reflecting pathological processes may have added value in assessing joint inflammation in rheumatoid arthritis (RA). Calprotectin (S100A8/9 protein) has been demonstrated…
  • Abstract Number: 2813 • 2014 ACR/ARHP Annual Meeting

    Correlation of Morning Stiffness with Measures of Higher Disease Activity in a Large US Registry Population of Rheumatoid Arthritis Patients

    Vibeke Strand1, Robert J. Holt2, Katherine C. Saunders3, Jeffery D. Kent4, Ping Xu5, Amy Y. Grahn4, Marc Mason3 and Carol J. Etzel6,7, 1Stanford University, Palo Alto, CA, 2University of Illinois - Chicago, Chicago, IL, 3Corrona, LLC., Southborough, MA, 4Horizon Pharma, Inc., Deerfield, IL, 5Axio Research LLC, Seattle, WA, 6PO Box 786, Corrona, LLC., Southborough, MA, 7Department of Epidemiology, UT MD Anderson, Houston, TX

    Background/Purpose : Morning stiffness may not be specifically queried by rheumatologists in the course of their regular interactions with rheumatoid arthritis (RA) patients.  This analysis…
  • Abstract Number: 2451 • 2014 ACR/ARHP Annual Meeting

    Mir-155 Expression Correlates with Clinical Disease Activity and Has Effector Function in Rheumatoid Arthritis

    Aziza Elmesmari1, Derek G. Gilchrist2, Mariola Kurowska-Stolarska3 and Iain B. McInnes4, 1Immunology, Institute of Infection,Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 2Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 3Institute of Infection,Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, 4Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: MicroRNAs are fine tuners of biological pathways that function via post-transcriptional regulation of target mRNA life span.  MicroRNA 155 (miR155) is particularly implicated in…
  • Abstract Number: 1920 • 2014 ACR/ARHP Annual Meeting

    Predicting SLE Disease Activity in the Next Year Based on Measures of Four Gene Transcripts and Two Proteins

    Laurence S Magder1, Eric Zollars2, Jadwiga Bienkowska3, Chris Stebbins4, Carrie Wager5, Linda Burkly6, Nicolas Wisniacki7, Ann Ranger8 and Michelle Petri9, 1Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD, 2Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Translational Medicine, Biogen Idec Inc., Cambridge, MA, 4Translational Medicine, Biogen Idec, Cambridge, MA, 5Biostatistics, Biogen Idec, Cambridge, MA, 6Biogen Idec, Cambridge, MA, 7Formerly with Biogen Idec, Cambridge, MA, 814 Cambridge Center, Biogen Idec, Cambridge, MA, 9Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose Multiple gene transcripts and proteins in blood or urine have been observed to correlate with disease activity in SLE. However some observed associations might…
  • Abstract Number: 1426 • 2014 ACR/ARHP Annual Meeting

    Periodontal disease and Clinical Activity of Rheumatoid Arthritis Patients

    Daniel Xibille-Friedmann1, Jose Ivan Martinez Rivera2, Jaqueline Rodriguez Amado3, Carolina Bustos Rivera Bahena4, Marisol Sandoval Rios5 and Jose Luis Montiel Hernandez6, 1Rheumatology, Hospital General de Cuernavaca, Cuernavaca, Mexico, 2Instituto Nacional de Salud Publica, Cuernavaca, Mexico, 3Universidad Autónoma de Nuevo Leon, Centro de Investigación y Desarrollo en Ciencias de la Salud, Monterrey, Mexico, 4Universidad Autonoma del Estado de Morelos, Science Faculty, Cuernavaca, Mexico, 5Universidad Autonoma del Estado de Morelos, Faculty of Pharmacy, Cuernavaca, Mexico, 6Cytokines and Autoimmunity Laboratory, Faculty of Pharmacy, Universidad Autónoma del Estado de Morelos, Cuernavaca, México, Cuernavaca, Mexico

    Background/Purpose: Although several studies have suggested the association between periodontitis, infection by Porphyromona gingivalisand Rheumatoid Arthritis disease activity, its relationship with periodontal disease, oral and…
  • Abstract Number: 1051 • 2014 ACR/ARHP Annual Meeting

    Rates of Renal Remission with Immunosuppressives in Lupus Nephritis: A Systematic Review and Network Meta-Analysis

    Jasvinder A. Singh1, Ahmed Kotb2, Alomgir Hossain2, Amy Mudano3 and George Wells4, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Ottawa, Ottawa, ON, Canada, 3Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, 4Cardiovascular Resarch Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada

    Background/Purpose To compare renal remission rates with immunosuppressives by performing a systematic review and network meta-analyses (NMA) of RCTs of lupus nephritis. Methods We performed…
  • Abstract Number: 687 • 2014 ACR/ARHP Annual Meeting

    Effect of Corticosteroid Use By Dose on the Risk of Developing Organ Damage over Time in Systemic Lupus Erythematosus—the Hopkins Lupus Cohort

    Sarah Al Sawah1, Xiang Zhang1, Baojin Zhu1, Laurence S. Magder2, Shonda A Foster1, Noriko Iikuni1 and Michelle Petri3, 1Eli Lilly and Company, Indianapolis, IN, 2Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, 3Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose:  Reduction of corticosteroid dose remains an important goal in the management of systemic lupus erythematosus (SLE). Current standard of care in SLE relies heavily…
  • Abstract Number: 384 • 2014 ACR/ARHP Annual Meeting

    Using Patient Reported Outcome Measures to Classify Disease Activity States in Rheumatoid Arthritis: A Comparison of Patient Activity Score (PAS) and Routine Assessment of Patient Index Data (RAPID)

    Erin Carruthers1, Noura AL Osaimi2, Charles H Goldsmith3, Paul Adam4 and Diane Lacaille5, 1Arthritis Research Centre of Canada, Richmond, BC, Canada, 2Rheumatology, University of Ottawa, Ottawa, ON, Canada, 3Health Sciences, Simon Fraser University, Burnaby, BC, Canada, 4Mary Pack Arthritis Centre, Vancouver, BC, Canada, 5Arthritis Research Centre of Canada, Vancouver, BC, Canada

    Background/PurposeIn RA the target for treatment is clinical remission or minimal disease activity. Patient involvement in monitoring their disease activity could enhance treatment by providing…
  • « Previous Page
  • 1
  • …
  • 85
  • 86
  • 87
  • 88
  • 89
  • …
  • 102
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology